Additive effects of combination treatment with anti-inflammatory and neuroprotective agents in experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 219, Issue 1-2, 2010, Pages 64-74

  Du, Sienmi ^a,b   Sandoval, Francisco ^a   Trinh, Pauline ^a   Voskuhl, Rhonda R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokine; Estrogen; Experimental autoimmune encephalomyelitis; Interferon beta; Multiple sclerosis

Indexed keywords

BETA INTERFERON; ESTROGEN RECEPTOR BETA; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 17; NICOTINAMIDE ADENINE DINUCLEOTIDE; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DENSITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ANTAGONISM; FEMALE; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MOUSE; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TH2 CELL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; IMMUNOLOGIC FACTORS; INTEGRIN ALPHA4BETA1; INTERFERON-BETA; LUMINESCENT PROTEINS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; MYELIN BASIC PROTEINS; NEUROPROTECTIVE AGENTS; NEUTROPHIL INFILTRATION; NITRILES; PEPTIDE FRAGMENTS; PROPIONATES; SEVERITY OF ILLNESS INDEX; SPINAL CORD;

EID: 77249101481     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.11.018     Document Type: Article

References (44)

1. Ali S., Coombes R.C. Estrogen receptor alpha in human breast cancer: occurrence and significance. J. Mammary Gland Biol. Neoplasia 2000, 5:271-281.
2. Arnason B.G.W. Immunologic therapy of multiple sclerosis. Annu. Rev. Med. 1999, 50:291-302.
3. Axtell R.C., Steinman L. Type 1 interferons cool the inflamed brain. Immunity 2008, 28:600-602.
4. Bauer M., Brakebusch C., Coisne C., Sixt M., Wekerle H., Engelhardt B., Fassler R. beta(1) integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc. Natl Acad. Sci. USA 2009, 106:1920-1925.
5. Billiau A. Anti-inflammatory properties of Type I interferons. Antiviral Res. 2006, 71:108-116.
6. Cannella B., Raine C.S. The Vcam-1/Vla-4 pathway is involved in chronic lesion expression in multiple-sclerosis (MS). J. Neuropathol. Exp. Neurol. 1993, 52:311-311.
7. Clanet M., Kappos L., Hartung H.P., Hohlfeld R. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult. Scler. 2004, 10:139-144.
8. Clanet M., Radue E.W., Kappos L., Hartung H.P., Hohlfeld R., Sandberg-Wollheim M., Kooijmans-Coutinho M., Tsao E.C., Sandrock A.W., Invest E.A.D.S. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002, 59:1507-1517.
9. Comabella M., Rio J., Espejo C., Ruiz de Villa M., Al-Zayat H., Nos C., Deisenhammer F., Baranzini S.E., Nonell L., Lopez C., Julia E., Oksenberg J.R., Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009, 130:145-150.
10. Domingues H.S., Krishnamoorthy G., Lassmann H., Wekerle H. Differential roles of Th1 and Th17 CD4+ T cell subsets in the pathogenesis of EAE. J. Neuroimmunol. 2008, 203:238-239.
11. Douin-Echinard V., Laffont S., Seillet C., Delpy L., Krust A., Chambon P., Gourdy P., Arnal J.F., Guery J.C. Estrogen receptor alpha, but not beta, is required for optimal dendritic cell differentiation and [corrected] CD40-induced cytokine production. J. Immunol. 2008, 180:3661-3669.
12. Elloso M.M., Phiel K., Henderson R.A., Harris H.A., Adelman S.J. Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J. Endocrinol. 2005, 185:243-252.
13. Fletcher J.M., Costelloe L., O'Farrelly C., Tubridy N., Mills K.H.G. IL-17 producing T cells and their induction in multiple sclerosis. Mult. Scler. 2006, 12:S219-S219.
14. Garidou L., Laffont S., Douin V., Krust A., Chambon P., Guy J.C., Guery J.C. Estrogen receptor alpha-signaling in inflammatory leukocytes is dispensable for 17 beta-estradiol-mediated inhibition of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 154:83-83.
15. Havrdova E., Galetta S., Hutchinson M., Stefoski D., Bates D., Polman C.H., O'Connor P.W., Giovannoni G., Phillips J.T., Lublin F.D., Pace A., Kim R., Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009, 8:254-260.
16. Honda K., Sawada H., Kihara T., Urushitani M., Nakamizo T., Akaike A., Shimohama S. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J. Neurosci. Res. 2000, 60:321-327.
17. Jaini R., Hannaman D., Johnson J.M., Bernard R.M., Altuntas C.Z., Delasalas M.M., Kesaraju P., Luxembourg A., Evans C.F., Tuohy V.K. Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis. Mol. Ther. 2006, 14:416-422.
18. Jansson L., Holmdahl R. Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum. 2001, 44:2168-2175.
19. Jansson L., Olsson T., Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J. Neuroimmunol. 1994, 53:203-207.
20. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
21. Liu H.B., Loo K.K., Palaszynski K., Ashouri J., Lubahn D.B., Voskuhl R.R. Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease. J. Immunol. 2003, 171:6936-6940.
22. Maret A., Coudert J.D., Garidou L., Foucras G., Gourdy P., Krust A., Dupont S., Chambon P., Druet P., Bayard F., Guery J.C. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur. J. Immunol. 2003, 33:512-521.
23. Martin-Saavedra F.M., Flores N., Dorado B., Eguiluz C., Bravo B., Garcia-Merino A., Ballester S. Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. Mol. Immunol. 2007, 44:3597-3607.
24. Martin-Saavedra F.M., Gonzalez-Garcia C., Bravo B., Ballester S. Beta interferon restricts the inflammatory potential of CD4(+) cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 2008, 45:4008-4019.
25. Martin-Saavedra F.M., Gonzalez-Garcia C., Bravo B., Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 2008, 45:4008-4019.
26. Mitra S.W. Immunolocalization of estrogen receptor beta in the mouse brain: Comparison with estrogen receptor alpha (vol 144, pg 2055, 2003). Endocrinology 2003, 144:2844-2844.
27. Morale M.C., Serra P.A., Caniglia S., Testa N., Tirolo C., L'Episcopo F., Gennusol F., Desole M.S., Marchetti B. Estrogen triggers astrocyte-microglia crosstalk in experimental Parkinsonism: implications for neuroprotection. Glia 2003, 26-26.
28. Morales L.B., Loo K.K., Liu H.B., Peterson C., Tiwari-Woodruff S., Voskuhl R.R. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J. Neurosci. 2006, 26:6823-6833.
29. Muraro P.A., Leist T., Bielekova B., McFarland H.F. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J. Neuroimmunol. 2000, 111:186-194.
30. Offner H. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. J. Neurosci. Res. 2004, 78:603-624.
31. Polanczyk M., Zamora A., Subramanian S., Matejuk A., Hess D.L., Blankenhorn E.P., Teuscher C., Vandenbark A.A., Offner H. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am. J. Pathol. 2003, 163:1599-1605.
32. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., Merkler D., Detje C., Gutcher I., Mages J., Lang R., Martin R., Gold R., Becher B., Bruck W., Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
33. Schaefer C., Hidalgo T.R., Cashion L., Petry H., Brooks A., Szymanski P., Qian H.S., Gross C., Wang P., Liu P., Goldman C., Rubanyi G.M., Harkins R.N. Gene-based delivery of IFN-beta is efficacious in a murine model of experimental allergic encephalomyelitis. J. Interferon Cytokine Res. 2006, 26:449-454.
34. Schmidt J., Sturzebecher S., Toyka K.V., Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J. Neurosci. Res. 2001, 65:59-67.
35. Shinohara M.L., Kim J.H., Garcia V.A., Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008, 29:68-78.
36. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13:139-145.
37. Stritesky G.L., Yeh N., Kaplan M.H. IL-23 promotes maintenance but not commitment to the Th17 lineage. J. Immunol. 2008, 181:5948-5955.
38. Stromnes I., Goverman J., Liggitt D. The role of IL-17 and IFN-gamma in defining pathogenic potential of T cells in EAE. Clin. Immunol. 2007, 123:S61-S62.
39. Tiwari-Woodruff S., Morales L.B., Lee R., Voskuhl R.R. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14813-14818.
40. Trapp B.D., Ransohoff R., Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 1999, 12:295-302.
41. Wang C., Dehghani B., Li Y., Kaler L.J., Vandenbark A.A., Offner H. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 2009, 126:329-335.
42. Wang C., Dehghani B., Li Y.X., Kaler L.J., Proctor T., Vandenbark A.A., Offner H. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J. Immunol. 2009, 182:3294-3303.
43. Wu T.W., Wang J.M., Chen S., Brinton R.D. 17 beta-Estradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-amp response element binding protein signal pathway and Bcl-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 2005, 135:59-72.
44. Wujek J.R., Bjartmar C., Richer E., Ransohoff R.M., Yu M., Tuohy V.K., Trapp B.D. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 2002, 61:23-32.